DiaSorin S.p.A.

As of June 30, 2026, DiaSorin S.p.A. carries a market capitalization of 3.35B, placing it among publicly traded companies globally. Its enterprise value stands at 4.18B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

DiaSorin S.p.A.'s next confirmed earnings release is scheduled for March 12, 2027.

As of June 30, 2026, DiaSorin S.p.A. has 49.50M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, DiaSorin S.p.A. maintains a current ratio of 1.79, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, DiaSorin S.p.A. recorded 16.71M in income tax expense.

As of the close on October 22, 2026, DiaSorin S.p.A.'s stock has gained approximately 2.18% over the past 52 weeks. The 50-day moving average sits at 76.22, while the 200-day moving average is 69.91.

As of June 30, 2026, DiaSorin S.p.A. holds 120.88M in cash and equivalents against 959.49M in total debt, resulting in a net debt position of 769.18M. Total book value stands at 1.42B, with working capital of 331.65M providing operational flexibility.